Search results
Results from the WOW.Com Content Network
Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker. The company's blockbuster Xarelto drug generated ...
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Bayer. $10.9 billion German pharmaceutical company Bayer agreed to pay nearly $11 billion to settle thousands of lawsuits over subsidiary Monsanto’s weed-killer Roundup. The settlement aims to ...
In 2020, Bayer settled most of the then-pending Roundup cases for up to $9.6 billion but failed to get a settlement covering future cases. More than 50,000 claims remain pending.
Individual lawsuits continued to fail because most states had laws shielding blood products from traditional product liability claims. [2] However, discovery was producing damaging documents contending that the companies had collected blood from high-risk donors like homosexuals and prisoners, intensifying informal settlement negotiations. [2]
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8 ]
Ultimately, the parties reached a settlement agreement of $430 million to resolve all civil claims and criminal charges stemming from the qui tam complaint. [ 3 ] [ 4 ] At the time of the settlement in May 2004, it represented one of the largest False Claims Act recoveries against a pharmaceutical company in U.S. history, and was the first off ...
Much of his case was initially dismissed by a trial judge, who agreed with Bayer that his failure-to-warn claims were barred by federal law. The 11th Circuit panel in July 2022 disagreed and ...